US 12,466,807 B2
Salt and crystal form of a FAK inhibitor
Christopher Burns, Melbourne (AU); and John Lambert, Melbourne (AU)
Assigned to Amplia Therapeutics Limited, Melbourne (AU)
Appl. No. 17/598,187
Filed by Amplia Therapeutics Limited, Melbourne (AU)
PCT Filed Mar. 27, 2020, PCT No. PCT/AU2020/050292
§ 371(c)(1), (2) Date Sep. 24, 2021,
PCT Pub. No. WO2020/191448, PCT Pub. Date Oct. 1, 2020.
Claims priority of application No. 2019901050 (AU), filed on Mar. 28, 2019.
Prior Publication US 2022/0340540 A1, Oct. 27, 2022
Int. Cl. C07D 401/12 (2006.01); A61K 9/00 (2006.01)
CPC C07D 401/12 (2013.01) [A61K 9/0053 (2013.01); C07B 2200/13 (2013.01)] 9 Claims
 
1. A crystalline form of a L-tartrate salt of a compound of formula I:

OG Complex Work Unit Chemistry
wherein the crystalline form has a characteristic powder diffraction pattern (XRPD) using Cu K radiation with major peaks at 2 theta values at about 9.1, 15.5, 17.0, 18.5, 21.8, 22.1, and 25.3.